title: A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro.
abstract: To improve tumor-to-tissue ratios of anticancer agents in radioimmunotherapy, a three-step targeting approach was used to deliver biotinylated liposomes to human ovarian cancer cells (NIH:OVCAR-3, SK-OV-3) in vitro. Targeting was based upon the use of two antibodies specific for the CA-125 antigen that is highly expressed on NIH:OVCAR-3 cells but not expressed on SK-OV-3 cells. Briefly, the approach consists of prelabeling target cells with biotinylated anti-CA-125 antibody and FITC-labeled streptavidin (SAv) prior to administration of biotinylated liposomes containing a marker dye for visualization by confocal laser scanning microscopy (CLSM). In addition, the two anti-CA-125 antibodies (B27.1 and B43.13) were labeled with FITC and incubated with ovarian cancer cells at 37 degrees C from 30 min to 24 h to study binding and uptake kinetics. Shedding kinetics of bound antibody from tumor cells was performed using radiolabeled B27.1. Results demonstrated that both B27.1 and B43.13 specifically bound to the cell surface of OVCAR-3 cells but not to SK-OV-3 cells. Biotinylation, FITC-labeling and radiolabeling of the antibodies did not compromise immunoreactivity. Less than 6% of the bound B27.1 was shed from tumor cells by 4 h following incubation, and the antibody-antigen complex resided predominantly on the cell surface by 4 h at 37 degrees C with slow internalization by 12-24 h. Biotinylated, conventional liposomes were specifically and effectively delivered to OVCAR-3 cells prelabeled with biotinylated B27.1 and SAv. The slow internalization and shedding properties of these antibodies are useful for multistep pretargeting methods. Thus, a modified targeting strategy, utilizing a bispecific antibody and liposomes, may be feasible for radioimmunoliposomal therapy of ovarian cancer.
authors.affiliation: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alta., T6G 2N8, Edmonton, Canada.
authors.forename: Z
authors.initials: Z
authors.lastname: Xiao
authors.forename: S A
authors.initials: SA
authors.lastname: McQuarrie
authors.forename: M R
authors.initials: MR
authors.lastname: Suresh
authors.forename: J R
authors.initials: JR
authors.lastname: Mercer
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: G G
authors.initials: GG
authors.lastname: Miller
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism*; D019921:Biotinylation; D018394:CA-125 Antigen / Q000276:immunology; D002277:Carcinoma / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D005260:Female; D016650:Fluorescein-5-isothiocyanate / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D008081:Liposomes; D010051:Ovarian Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D016499:Radioimmunotherapy / Q000379:methods; D019809:Streptavidin / Q000737:chemistry; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D008081:Liposomes; D019809:Streptavidin; D016650:Fluorescein-5-isothiocyanate